View Author
patient study cycle cancer treatment irinotecan pki 166 grade docetaxel pharmacokinetic phase -014813 toxicity dose level su -014813 level 2 weeks tumor table diarrhea oncol 4 weeks trial activity plasma analysis result therapy disease neutropenia chemotherapy day 1 response inhibitor hd-ct 3 weeks marker growth combination kinase transaminase survival elevation administration effect phase i study hd-vip factor phase i toxicitie etoposide cisplatin erasmus universiteit rotterdam tyrosine 750 mg inhibition capsule high-dose sample dosing decline metastatic colorectal cancer semisolid matrix capsules concentration cyp 3a receptor schedule -38 dose levels volume 22 | marker decline transaminase elevations study drug 75 mg /m high-dose chemotherapy sn -38 group 70 mg /m fever colorectal
4 Most Recent Publications
|
Phase i safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
(Article)
Jonge, M.J.A. de Dumez, H. Kitzen, J.J.E.M. Beuselinck, B. Verweij, J. Courtney, R. Battista, A. Brega, N. Schöffski, P. |
2011-06-01
|
|
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
(Article)
Daugaard, G. Skoneczna, I. Schmoll, H.J. Aass, N. Wit, R. de de Santis, M. Dumez, H. Marreaud, S. Collette, L.A.J. Lluch, J.R.G. Bokemeyer, C. |
2011-05-05
|
|
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
(Article)
Hoekstra, R. Dumez, H. Fidler, I.J. Oosterom, A.T. van Verweij, J. Eskens, F.A.L.M. Gaast, A. van der Planting, A.S.Th. Heus, G. de Sizer, K.C. Ravera, C. Vaidyanathan, S. Bucana, C. |
2005-10-01
|
|
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
(Article)
Soepenberg, O. Dumez, H. Levebvre, P. Assadourian, S. Sanderink, G.J. Sparreboom, A. Oosterom, A.T. van Verweij, J. Jong, F.A. de Jonge, M.J.A. de Thomas, J. Eskens, F.A.L.M. Schaik, R.H.N. van Selleslach, J. Steeg, J. ter |
2005-02-15
|
